Skip to content

SION SION Return on equity

Return on equity at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
24.2%
AbbVie logo
AbbVieABBV
89%+32.7pp
Septerna, Inc. logo
Septerna, Inc.SEPN
-12.2%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-49.6%+34.2pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
22.5%+10.1pp

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.8B
Enterprise value$1.74B

Returns & leverage

See full
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Calculated from SION’s reported figures.

Based on trailing twelve months.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's return on equity?
SION (SION) reported return on equity of -26.7% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.